We developed anticancer drug-conjugated biodegradable polymer-nanoparticle-loaded adiposederived stem cells (AdScs) as a tool for biodrug delivery systems for cancer therapy. pirarubicin was conjugated in polylactic/glycolic acid (pLGA) followed by formation of nanoparticles (nps), which were loaded with human AdScs and cocultured. the pirarubicin-conjugated pLGA np-loaded AdScs (PirNP-AdSCs) were overall viable within 48 h and exhibited significantly enhanced migration activity. We confirmed that pirarubicin was gradually released into the culture medium from PirNP-AdSCs, and the conditioned medium significantly inhibited the proliferation activity and induced the apoptosis of human pancreatic cancer cells (KP1N). PirNP-AdSCs also significantly induced tumor cell apoptosis in an ex vivo culture system with KP1N-derived tumors, and there was increased invasion/migration of PirNP-AdSCs inside the tumor. Finally, we compared the therapeutic efficacy of the PirNP-AdSCs on KP1Nderived tumor growth with that of treatments of AdScs alone, pirnps alone or normal saline (control) in immunodeficient mice. Subcutaneous local administration of PirNP-AdSCs significantly inhibited tumor growth, inducing the apoptosis of tumor cells and vasculature compared with the other groups. the present therapeutic strategy might give rise to a novel cancer therapy minimizing the adverse side effects of anticancer drugs in patients who suffer from cancer.
Pancreatic cancer is highly malignant and is the fourth most common cause of death due to cancer in Japan and in the US 1 . Pancreatic cancer patients have a poor prognosis, with statistical data indicating that the 5-year relative survival rate is currently 8%. Resection is the only an opportunity for a cure, but approximately half of the patients with pancreatic cancer already have metastases at the time of diagnosis. Standard chemotherapy is ineffective to improve the poor prognosis. Even if chemotherapy is performed, adverse events appear frequently 2 , so adequate treatment is difficult to achieve for patients with poor prognosis. Therefore, an efficient drug delivery system (DDS) seems to be important for future chemotherapy.
Mesenchymal stem cells have multiple characteristics and have received attention for their contrasting roles in cancer cell behavior. For instance, bone marrow-derived stem cells inhibit the proliferation of Kaposi's sarcoma cells 3 . In addition, mesenchymal stem cells promote the proliferation of tumor cells derived from colon cancer, breast cancer and melanoma 4, 5 . Mesenchymal stem cells are present not only in embryonic tissues such as bone marrow, skin, and placenta but also in adipose tissue. Like bone marrow-derived stem cells, adipose-derived stem cells (AdSCs) have been reported to both inhibit and promote cancer-derived cell proliferation. AdSCs promote the tumor growth of colon, lung, breast, glioblastoma and thyroid cancer [6] [7] [8] [9] . However, AdSCs also inhibit pancreatic cancer and prostate cancer with metastasis growth in vitro and in vivo [10] [11] [12] . Based on the evidence that AdSCs have the ability to be recruited to sites of tumor via an NF-kB-involved signaling pathway 13 , AdSCs have been used as a vehicle for carrying viruses or nanoparticles (NPs) beyond the blood-brain barrier to brain tumors 14, 15 .
The aim of this study was to develop a novel hybrid treatment for pancreatic cancer utilizing AdSCs and anticancer drugs with a slow drug-release system. We tested the hypothesis that when anticancer-drug-NP-loaded AdSCs are applied to tumor sites, AdSCs recruited to the tumor sites would not only exhibit an inhibitory effect on pancreatic cancer cell proliferation but also inhibit cancer cell proliferation with the slow release of anticancer drugs upon PLGA degradation, inducing apoptosis. The combination of anticancer-drug-loaded PLGA NPs and AdSCs could be a novel and effective therapy against pancreatic cancer that exhibits few adverse side effects.
Internal Medicine (II), Faculty of Medicine, Osaka Medical College, Osaka, Japan. *email: in2030@osaka-med.ac.jp open patients undergoing a second cesarean section. The Osaka Medical College Ethics Committee approved this study (Protocol No. 1040-01), and all methods were performed in accordance with the relevant guidelines and regulations. Informed written consent was obtained from all subjects. The hAdSCs were isolated from the adipose tissue as previously described with minor modifications 16 . Briefly, the adipose tissue was washed in phosphate-buffered saline (PBS), minced, and digested in 5 ml of Liberase TM Research Grade (Sigma-Aldrich Japan K.K., Tokyo, Japan) (0.5 mg/ml in 1% bovine serum albumin (BSA)/Hanks' balanced saline solution; Roche Diagnostics, K.K., Tokyo, Japan) for 15 minutes at 37 °C. The digested tissue was filtered through a 40-mm cell strainer (BD Falcon, Tokyo, Japan) and centrifuged at 450 RCF for 10 minutes. The supernatant containing adipocytes and debris was discarded. The pelleted cells were collected as the stroma vascular fraction (SVF), and the number of cells not stained by trypan blue and sized 5-30 mm was measured using a conventional cytometer (LUNA; Logos Biosystems, Inc., Annandale, VA). The freshly isolated SVFs were cultured in 10% fetal bovine serum (FBS)/ Dulbecco's modified Eagle's medium (DMEM)-F12 containing antibiotics on plastic dishes at a density of 10 4 / cm 2 under conditions of 5% CO 2 and 37 °C. Adherent cells were passaged between passages 3 and 6 and used as maximum hAdSCs for the experiments 17 .
KP1N human pancreatic cancer cells were purchased from the JCRB (Japanese Collection of Research Bioresources) Cell Bank. The cells were maintained in DMEM supplemented with 10% FBS and 1% penicillin/ streptomycin (Life Technologies, Burlington, Ontario, Canada).
pirarubicin-conjugated pLGA (pir-pLGA) np. A PLGA NP was generated as described previously 18 Briefly, 25 mg of PLGA (#B6017-1 50:50 DL-PLG, Corefront, Inc.) and 4 mg of pirarubicin (Sigma-Aldrich) were dissolved in 1 ml of acetone. The solution was then placed in 20 ml of a 2% polyvinyl alcohol (PVA)/distilled water mixture and irradiated with an ultrasonic wave at a power level of 1.0 (Sonicator 3000, Misonix Inc.) for 10 minutes followed by stirring for 16 h to evaporate the acetone. Then, the supernatant was collected after centrifugation at 200 RCF for 10 minutes and further centrifuged at 15000 RCF for 30 minutes with additional distilled water for washing. The washing step was repeated 3 times, and PBS was added to the pellet and stirred with a homogenizer at 10,000 rpm for 10 minutes to disperse the NPs. Finally, the solution was freeze-dried using a lyophilizer (VD-550R, TAITEC, Tokyo, Japan) for over 48 h. The freeze-dried powder was used for all the experiments. We generated rhodamine-labeled Pir-PLGA NPs the same method by mixing rhodamine with pirarubicin as a landmark of incorporated NPs to AdSCs. Uptake of pir-pLGA nps in AdScs and release pattern of pirarubicin from AdScs. Pir-PLGA NPs (0, 10, 25, 50 and 100 µg) were coincubated with adhered AdSCs for 30 minutes, and the uptake of Pir-PLGA in the AdSCs was visualized by a fluorescence confocal microscope (TCS SP8, Leica, Inc.) Spontaneous fluorescent signals were detected from Pir-PLGA loaded in the AdSCs. To evaluate the release of pirarubicin, the Pir-PLGA NPs (500 µg) were loaded onto the AdSCs (10 6 cells) and maintained in Dulbecco's modified Eagle medium/ Nutrient Mixture F-12 (DMEM/F-12, no phenol red) with 0% FBS. The culture medium was changed at 8, 24, 48, 72, and 96 h after initial plating. The concentration of pirarubicin in the collected medium was quantified by fluorometry. The fluorescence was measured using an EnSpire ® Multimode Plate Reader (PerkinElmer, Inc., Waltham, MA) at excitation/emission wavelengths of 470/585 nm. cell proliferation assay. The proliferation activity of AdSCs was examined using the Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto, Japan) according to the manufacturer's instructions. Briefly, the Pir-PLGA NPs (0, 10, 25, 50 and 100 µg) or PLGA NPs (0, 10, 25, 50 µg) were incorporated into the AdSCs (1 × 10 5 cells). The AdSCs were then seeded onto 96-well culture plates at a density of 1.0 × 10 4 cells per well and cultured in DMEM/ F12 containing 10% FBS for 24 or 48 h at 37 °C. For the coculture assays, KP1N cells were cocultured with AdSCs using a Transwell TM separate culture system for 48 h. A total of 1.0 × 10 5 KP1N cells and 1.0 × 10 4 AdSCs at a ratio of 10:1 were cultured in complete 10% FBS/DMEM. cell migration assay. The migration activity of Pir-PLGA NP-loaded AdSCs was evaluated by a migration assay using a Transwell TM insert with a 5.0 μm pore size for 24-well plates (Sigma-Aldrich). Briefly, the Pir-PLGA NPs or PLGA NPs (0, 10, 25, 50 and 100 µg) were incorporated into the AdSCs (1.0 × 10 5 cells). Two different approaches were adopted. First, a plate well was filled with AdSC growth medium (DMEM/F12 600 μl) with 20% FBS. The insert chamber was used to accommodate 2.0 × 10 4 AdSCs in DMEM/F12 (200 μl) with 0% FBS. A second plate well was filled with tumor growth medium (DMEM 600 μl) with 10% FBS and 5.0 × 10 4 KP1N cells. AdSCs in DMEM/F12 (200 μl) with 10% FBS were placed in the insert chamber. The cells were allowed to migrate for 4 h or 16 h at 37 °C, immediately followed by cell fixation with 4% paraformaldehyde (PFA). The nuclei were counterstained with DAPI (Sigma). The number of AdSCs on the basolateral side was counted under a computer-assisted fluorescence/light microscope BioZero BZ-X700 (Keyence, Osaka, Japan). cell apoptosis assay. Pir-PLGA NPs (0, 10, 25, 50 and 100 µg) were incorporated into the AdSCs (1.0 × 10 5 cells), and the Pir-PLGA NP-loaded AdSCs were cultured in DMEM/F12 containing 10% FBS for 48 h at 37 °C. The nuclei were counterstained with DAPI, a terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay (In Situ Cell Detection Kit, TMR red, Roche) was performed, and the cells were immediately observed under a computer-assisted fluorescence/light microscope (BioZero BZ-X700, Keyence, Osaka, Japan). For the coculture assays, 50 µg of Pir-PLGA NPs was incorporated into the AdSCs (1.0 × 10 5 cells). The KP1N cells were cocultured with AdSCs using transwells. A total of 1.0 × 10 5 KP1N cells and 1.0 × 10 4 AdSCs at different ratios (10:1) were cultured in complete DMEM with 10% FBS for 48 h. The KP1N cell nuclei were counterstained Assessment for adsc recruitment to tumor and pancreatic cancer cell apoptosis. A total of 2.0 × 10 6 KP1N cells with 60 μL of Matrigel TM were injected subcutaneously into the dorsal skin of 6-to 8-week-old female NOD-SCID mice to create an in vivo model of pancreatic cancer. On day 21, the xenografts were harvested and cocultured with NP-loaded (Pir-PLGA NPs and rhodamine-conjugated PLGA NPs) AdSCs in DMEM/F12 with 10% FBS in 24-well plates for 7 days.
immunohistochemistry. The KP1N-derived xenografts were harvested on day 42. The tumors were fixed for 6 h in 4% PFA and incubated overnight in a 15% sucrose solution. The tissues were embedded in optimal cutting temperature (OCT) compound (Sakura FineTek, Japan) and sectioned at a 6-mm thickness. Fluorescent immunostaining was performed to detect tumor apoptosis and vascularity. The TUNEL assay (DeadEnd TM Fluorometric TUNEL system, Promega) was used as a marker for apoptotic cells. Isolectin B4 (ILB4) (1:100; Vector Laboratories) was used for capillary staining with the DyLight 549 streptavidin-biotin binding method. Anti-mouse CD3 and F4/80 antigen (1:100; Thermo Fisher Scientific) were used for staining inflammatory cells with a secondary antibody of Alexa Fluor 594-conjugated IgG. The nuclei were counterstained with DAPI, and the sections were mounted in aqueous mounting medium. The images were examined under a computer-assisted fluorescence/light microscope (BioZero BZ-X700, Keyence, Osaka, Japan).
Histological analysis. The KP1N-derived xenografts were harvested on day 42. The tumors were fixed for 6 h in 4% PFA and incubated overnight in a 15% sucrose solution. The tissues were embedded in OCT compound and sectioned at a 6-mm thickness. Masson's trichrome staining was performed to evaluate tumor fibrosis. The Statistical analysis. All values are expressed as the mean ± s.e.m. Statistical analyses were performed using Prism TM software (GraphPad Software, CA, USA). Nonparametric unpaired t-tests (Mann-Whitney U-test) were used for comparisons between two groups, and repeated-measure two-way ANOVA with Bonferroni post hoc tests were used for comparing multiple groups. P values less than 0.05 were considered statistically significant.
Results
Uptake of Pir-PLGA NPs in AdSCs and extracellular release of pirarubicin. We first generated and examined several kinds of Pir-PLGA NPs for the experiments. The amount of pirarubicin increased in the NPs in a dose-dependent manner. (Suppl. Fig. 1 ) In this study, we used 25 mg PLGA (50:50) and 4.0 mg pirarubicin to form the Pir-PLGA NPs. The average size of the Pir-PLGA NPs were 357.3 ± 10 nm.
We confirmed the loading of Pir-PLGA NPs in the AdSCs under a confocal laser microscope. The Pir-PLGA NPs were excited by a laser at 560 nm wavelength, and the AdSCs were visualized in red; in this way, the dose-dependent uptake of Pir-PLGA NPs in the AdSCs could be observed. (Fig. 1a) We also confirmed the release pattern of pirarubicin by measuring its concentration in medium with Pir-PLGA NP-loaded AdSCs (500 µg/1 × 10 6 of AdSCs). Pirarubicin was gradually released up to 48 h after uptake of Pir-PLGA NPs in the AdSCs. Although a large number of Pir-PLGA NP-loaded AdSCs died 7 days after incubation, the attached/survived AdSCs still contained 1.92 ± 0.3% pirarubicin.
pir-pLGA np loading did not alter AdSc migration activity but inhibited proliferation activity.
We assessed the cell functions of Pir-PLGA NP-loaded AdSCs to evaluate the influence of Pir-PLGA on the AdSCs following 48 h of incubation. The proliferation of Pir-PLGA NP-loaded AdSCs significantly declined in a dose-dependent manner (Fig. 2a ), and the trend was similar to that following 16 h and 24 h of incubation. (Suppl. Fig. 1b ) The apoptosis of AdSCs was induced at high doses of 50 µg < 100 µg. (Fig. 2c) The migration of AdSCs toward FBS-containing medium declined at 16 h ( Fig. 2b) but increased toward KP1N cells after uptake of PLGA NPs (Fig. 2d ) and even with Pir-PLGA NPs. (Fig. 2e ) At a short time (4 h) after uptake of Pir-PLGA NPs, the migration of AdSCs toward the FBS-containing medium did not decline. (Suppl. Fig. 3b ) In addition, 
Pir-PLGA NP-loaded AdSCs inhibited KP1N cell-derived tumor growth. The KP1N cells were
inoculated in the NOD-SCID mice subcutaneously. On day 21 after xenograft transplantation, 5.0 × 10 5 AdSCs (250 µg Pir-PLGA NP-loaded or none) or only Pir-PLGA NPs (250 µg) were transferred to the margin of the tumor. Tumor volume measurement was performed once a week. Tumor growth was inhibited in the order of Pir-PLGA NP-loaded AdSCs, AdSCs and Pir-PLGA NPs only. (Fig. 5a,5b) The tumors were harvested on day 21 after injection of Pir-PLGA NP-loaded AdSCs, AdSCS, or Pir-PLGA NPs only. Histological analysis performed to assess tumor fibrosis ( Fig. 5c ) showed that fibrosis was low and in the order of Pir-PLGA NP-loaded AdSCs, AdSCs and Pir-PLGA NPs only on the marginal and central sites. (Fig. 5d ) Fluorescent immunostaining was 
Discussion
In the present study, we demonstrated that Pir-PLGA NP-loaded AdSCs reduced the growth of pancreatic cancer by inhibiting KP1N proliferation and inducing apoptosis both in vitro and in vivo. PLGA protects drug molecules and provides physicochemical stability 20 . NPs are taken up by cells more efficiently than larger micromolecules and, therefore, could be used as an effective delivery system and have been extensively investigated 21, 22 .
We first examined Pir-PLGA NPs made of PLGA NP and pirarubicin compounded at different proportions. When the encapsulation efficiency was high, the amount of pirarubicin appearing on the surfaces increased, and the PLGA NP negatively affected cell viability after being taken up by the AdSCs. (data not shown). In this study, we used 25 mg of Pir-PLGA NP compounded with 25 mg of PLGA (50:50) and 4.0 mg of pirarubicin for the experiments. Our in vitro results demonstrated that a high dose of Pir-PLGA NPs (50 µg Pir-PLGA NPs in www.nature.com/scientificreports www.nature.com/scientificreports/ 1.0 × 10 5 AdSCs) negatively influenced the viability of the AdSCs, while a high dose of Pir-PLGA NP-loaded AdSCs effectively inhibited cancer cell proliferation. In addition, even a high dose of Pir-PLGA NPs did not influence migration activity for at least 16 h (incubation time in a 5% CO 2 incubator), suggesting that the Pir-PLGA NP-loaded AdSCs could migrate into the inside of the tumor, releasing pirarubicin, which could lead to effective anticancer therapy. In an ex vivo experiment, we also confirmed the accumulation and migration of AdSCs inside the tumor, resulting in tumor cell and vascular apoptosis. Specifically, this experiment was conducted with a dose of Pir-PLGA NPs to minimize the inhibitory effect on migration activity, which is one of the important mechanisms by which AdSCs enter the central site of the tumor. This dose of Pir-PLGA NPs also minimized the apoptosis of AdSCs (less than 5% in 48 h after uptake of Pir-PLGA NPs). Based on the results of the in vitro and ex vivo experiments, we finally decided to use a dose of 50 µg Pir-PLGA NPs in 1.0 × 10 5 AdSCs for the in vivo experiments. In vivo experiments, we first challenged intravascular administration of AdSCs as previous report 13 , that MSCs injected to left ventricular cavities accumulated to subcutaneous tumor. This thought to be ideal place of administration, but we could not confirm the accumulation of AdSCs (data not shown). This time we chose the method to inject to the marginal site of the tumor.
Immunofluorescence staining indicated that cell apoptosis at the central site of the tumor, including tumor blood vessels, was significantly higher in Pir-PLGA NP-loaded AdSCs than in the other treatment groups. As a result, the vascularity of the tumors was reduced in the Pir-PLGA NP-loaded AdSC group, suggesting that the AdSCs carried Pir-PLGA NPs to the central site, releasing pirarubicin. Indeed, the numbers of AdSCs recruited to the tumor and apoptotic tumor cells were significantly increased at the central site in the Pir-PLGA NP-loaded AdSC group. The inhibition of tumor growth by Pir-PLGA NP-loaded AdSCs is attributed to the dual effect of the released pirarubicin, which has an inhibitory effect on DNA replication and secreted anti-pancreatic cancer factors, i.e., TRAIL 23 , transcriptional intermediary factor 1 gamma (Tif1gamma) 24 , and microRNA-145 25, 26 , and from the recruited AdSCs on proliferating/apoptotic tumor and vascular cells. Vascular cell apoptosis, which was frequently observed in the Pir-PLGA NP-loaded AdSC group, is also considered a crucial finding/mechanism by which the nutrient/blood supply for tumor growth was reduced. The antiinflammatory effect of AdSCs is also considered a possible reason why AdSCs reduce tumor growth by increasing CD4-positive regulatory T cells inhibiting IL-17 production 27 . However, we could not assess the reason because inflammatory cells were not observed in the tumors in any experimental groups (Suppl. Fig. 4 ) as NOD-SCID mice lack T cells and B cells and have reduced macrophage function [28] [29] [30] . Although there was less inflammation in the tumors, fibrosis derived from the host/mouse tissue that was required for tumor growth could be observed, and the extent of tumor fibrosis was significantly reduced in the Pir-PLGA NP-loaded AdSC group.
We also compared the effect of single treatment versus multiple treatments on the tumor growth of xenografts. In a previous study on human gastric cancer, the group that received a weekly low-dose treatment had better outcome than the group that received a high-dose treatment every 3 weeks 31 . In contrast, our study indicated that a single high-dose treatment was significantly more effective than multiple low-dose (1/3 of the high dose) treatments. Histological findings for these two groups showed that there was a large difference in the percentage of vascular apoptosis between the marginal site and the central site of the tumor. The multiple low-dose treatment induced tumor cell and vascular apoptosis in the marginal site but not in the central site of the tumor, suggesting that a small number of Pir-PLGA NP-loaded AdSCs were not able to enter the tumor due to their spontaneous apoptosis as a result of pirarubicin release even though they could reach the marginal site during all three treatments. In contrast, some Pir-PLGA NP-loaded AdSCs that reached the marginal site might have been able to enter the tumor even during the single treatment, inducing tumor cell and vascular apoptosis in the central site of the tumor, which effectively reduced the tumor size. In general, pirarubicin is administered to patients at a dose of 40-60 mg/body for breast cancer, gastric cancer, and ovarian cancer in clinical settings. For NOD-SCID mice 32 , this dose corresponds to approximately 160-245 µg/mouse. The theoretical dose of pirarubicin administered in this study was 0.891 µg (pirarubicin/PLGA NP = 3.564 µg/mg × 0.25)/mouse, which was drastically low. Thus, the burden on the body would be considered to be minimal compared with that in general systemic chemotherapy. For this reason, anticancer therapy with Pir-PLGA NP-loaded AdSCs will allow us to repeat the treatment without inducing severe side effects in patients.
This study has some limitations. First, although intravascular administration of AdSCs thought to be ideal place of administration, we chose the method to inject to the marginal site of the tumor. Second, evaluation of effect of drug-loaded AdSCs against tumor growth is only based on morphological data that no molecular data is included. Adding molecula data may reveal more interesting facts, therefore further research is desired in the future.
In conclusion, we have demonstrated that only a single local treatment with Pir-PLGA NP-loaded AdSCs effectively inhibited the growth of human pancreatic cancer cell-derived xenografts, inducing tumor cell apoptosis in mice. Our results obtained in this study may give rise to a novel, next-generation anticancer therapy not only for pancreatic cancer but also for other types of cancers.
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